Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
RenovoRx ( (RNXT) ) has provided an update.
On November 14, 2025, RenovoRx, Inc. entered into a Capital on Demand™ Sales Agreement with JonesTrading Institutional Services LLC, allowing the company to issue and sell up to $3,723,029 in shares of its common stock. This agreement, which involves at-the-market offerings or negotiated transactions, is part of RenovoRx’s strategy to leverage its shelf registration statement, extending its ability to raise capital and potentially impacting its market positioning by enhancing financial flexibility.
The most recent analyst rating on (RNXT) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on RenovoRx stock, see the RNXT Stock Forecast page.
Spark’s Take on RNXT Stock
According to Spark, TipRanks’ AI Analyst, RNXT is a Neutral.
RenovoRx’s overall stock score reflects significant financial instability with persistent losses and negative cash flows. Despite technical analysis suggesting some short-term upward momentum, the company’s valuation is weakened by a negative P/E ratio and lack of profitability. The absence of earnings call data and corporate events limits further insights into potential improvements, maintaining a cautious outlook on its stock performance.
To see Spark’s full report on RNXT stock, click here.
More about RenovoRx
RenovoRx, Inc. operates in the healthcare industry, focusing on innovative therapies and delivery systems for cancer treatment. The company is known for its specialized products aimed at improving the efficacy and safety of cancer therapies, with a market focus on enhancing patient outcomes.
Average Trading Volume: 568,355
Technical Sentiment Signal: Sell
Current Market Cap: $36.65M
For an in-depth examination of RNXT stock, go to TipRanks’ Overview page.